ArticleJournal for immunotherapy of cancer2019
Could the menagerie of the gut microbiome really cure cancer? Hope or hype.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients.Frontiers in oncology · 2022Pooled it
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway.Cellular & molecular biology letters · 2026Article
- The intricate interplay of microbial metabolomics and carcinogenesis: a spotlight on mechanistic pathways, clinical implications and methodological challenges.Frontiers in cellular and infection microbiology · 2026Review
- Review
- Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies.Therapeutic advances in drug safety · 2025Article
- Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2023Article
- Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2023Article
- Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.Journal for immunotherapy of cancer · 2021Article
- Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?Human vaccines & immunotherapeutics · 2021Review
- Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients.Frontiers in microbiology · 2021Article
- Influence of gut microbiome on multiple myeloma: friend or foe?Journal for immunotherapy of cancer · 2020Article
- Microbiomes for All.Frontiers in microbiology · 2020Review
- Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions.Biomarker research · 2020Review
- Commentary: Dietary methionine influences therapy in mouse cancer models and alters human metabolism.Frontiers in oncology · 2020Article
- Probiotics in health and disease: fooling Mother Nature?Infection · 2019Review
- Gut microbiome and CAR-T therapy.Experimental hematology & oncology · 2019Review
- Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.Frontiers in immunologyReview
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of microbiome's role in the immunotherapy setting. The microbiome research pipeline is ripe for large-scale, prospective trials. Working knowledge of immune-based cancer treatments, heterogeneity in their responses and resistance mechanisms, relevant immunological and microbiological pathways and potential for gut microbiome in enhancing the responses, is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.